Creatine Supplementation In Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial
Notes for this study:
||By the end of the 16-week trial, both groups had decreased total fibromyalgia impact questionnaire FIQ scores. However, this change was not statistically significant within or between groups. Total FIQ scores (range 0-100). Mean and SD. Placebo group - Pre: 62.2 ± 0.8. Post: 48.1 ± 16.3. Delta: —14.1 ± 16.2. Effect size: —1.3. Creatine group - Pre: 65.3 ± 10.4. Post: 52.6 ± 18.5. Delta: —12.7 ± 1.0. Effect size: –1.2. Placebo vs. creatine group: Difference in delta: —1.4 ± 7.0. 95% Confidence interval: —15.2, 12.4. P = 0.42.
|Number of Subjects
||30-44, 45-64, 65+
This randomized controlled trial had the subjects consume either creatine monohydrate or a placebo for 16-weeks. The participants in the creatine arm began taking 20 grams for 5 days divided into 4 equal doses, which was then followed by consuming 5 grams daily for the rest of the intervention. The placebo group was given the same protocol but consumed dextrose. Muscle function, aerobic conditioning, cognition, quality of sleep, kidney function and muscle phosphorylcreatine content was measured before and after the study.
There were improvements in leg and chest press strength and increased intramuscular phosphocreatine content. However, there were no statistically significant improvements in symptoms of fibromyalgia and quality of life.